Dudediligence.

Summit Therapeutics Inc

SMMTNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$0.00Dec ’24
Net income, by quarter
−$56.3MSep ’24−$61.2MDec ’24−$62.9MMar ’25−$565.7MJun ’25−$231.8MSep ’25−$219.2MDec ’25−$189.4MMar ’26−$215.7MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$1.8M$705,000$0.00$0.00none on file
Operating income−$86.2M−$72.1M−$609.6M−$226.0Mnone on file
Net income−$88.6M−$78.8M−$614.9M−$221.3M−$1.08B
Operating cash flow−$72.6M−$41.6M−$76.8M−$142.1M−$322.9M
Free cash flow−$72.9M−$42.2M−$76.9M−$142.2M−$323.6M
Cash$71.8M$348.6M$71.4M$104.9M$225.3M
Shares outstanding98.0M211.1M701.7M737.6M775.4M